Last reviewed · How we verify
Medipost, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| CARTISTEM® + Debridement | CARTISTEM® + Debridement | phase 3 | Allogeneic mesenchymal stem cell therapy | Orthopedics / Regenerative Medicine |
Therapeutic area mix
- Orthopedics / Regenerative Medicine · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Anterogen Co., Ltd. · 1 shared drug class
- Cell Biopeutics Resources Sdn Bhd · 1 shared drug class
- Kang Stem Biotech Co., Ltd. · 1 shared drug class
- Mesoblast, Ltd. · 1 shared drug class
- Pharmicell Co., Ltd. · 1 shared drug class
- Tigenix S.A.U. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Medipost, Inc.:
- Medipost, Inc. pipeline updates — RSS
- Medipost, Inc. pipeline updates — Atom
- Medipost, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Medipost, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medipost-inc. Accessed 2026-05-16.